
Shockwave Medical has recently acquired Neovasc
We’re committed to driving value for physicians and improving the lives of an underserved patient population.
A LEADER IN CARDIOVASCULAR INNOVATION
Neovasc is a leader in the development of minimally invasive therapies for two of the most vexing challenges in cardiovascular care: refractory angina and mitral valve regurgitation.
The company is committed to clinical rigor and collaborates with researchers and clinicians in Canada, the United States, Europe, and the Middle East. Our products, the Reducer™ and Tiara™ systems, represent the forefront of innovation in treating advanced heart disease.
Reducer is CE-marked for use in the EU and is FDA approved for investigational use in the US. Tiara is not commercially available and is currently being evaluated in two ongoing clinical trials.
Headquartered in Vancouver, BC and Minneapolis, MN, Neovasc is publicly traded on both the NASDAQ and the Toronto Stock Exchange (NVCN).
BRITISH COLUMBIA
13700 Mayfield Place #2135
Richmond BC V6V 2E4
1-855-802-5180
email >
MINNESOTA
900 Long Lake Road
Suite 300
New Brighton, MN 55112
email >
LEADERSHIP AND GUIDANCE
President and Chief Executive Officer
Chief Operating Officer
Chief Financial Officer
Vice President, Regulatory Affairs
Global Angina Therapies
Vice President of Clinical Affairs
Chief Quality Officer
MD, Medical Director
Fred Colen
President and Chief Executive Officer

Bill Little
Chief Operating Officer

Christopher Clark
Chief Financial Officer

Lisa Becker
Vice President, Regulatory Affairs
Global Angina Therapies

Sarah Gallagher
Vice President of Clinical Affairs

John Panton
Chief Quality Officer

Prof. Shmuel Banai
MD, Medical Director
